Curaleaf Holdings Inc
TSX:CURA

Watchlist Manager
Curaleaf Holdings Inc Logo
Curaleaf Holdings Inc
TSX:CURA
Watchlist
Price: 5.1 CAD 37.84% Market Closed
Market Cap: 3.9B CAD

Curaleaf Holdings Inc
Investor Relations

Curaleaf Holdings Inc., a prominent player in the burgeoning cannabis market, has carved out a significant niche for itself by fully integrating its operations from cultivation to distribution. Founded in 2010, the Massachusetts-based company has rapidly grown to become one of the largest cannabis retailers in the United States. With a keen eye on the complex regulatory landscape, Curaleaf has strategically expanded its footprint across multiple states, adapting to various state laws and regulations. Their operational strategy hinges on vertical integration, meaning they control every stage of the cannabis supply chain. This allows Curaleaf not only to maintain high product quality and consistency but also to maximize margins by reducing costs and gaining efficiencies at all levels of production and retailing.

Generating revenue through a combination of wholesale and retail sales, Curaleaf has established a range of products including cannabis flower, oils, edibles, and topical treatments, catering to both medical and recreational customers. The company's retail outlets, spanning across multiple states, are crucial in driving sales, where knowledgeable staff guide customers through intricate product offerings aimed at satisfying diverse consumer needs. Meanwhile, Curaleaf’s wholesale division supplies products to other retail outlets, expanding its market reach and solidifying its brand presence. The synergy between its retail prowess and wholesale operations has allowed Curaleaf to sustain steady revenue growth, positioning it well in a highly competitive and rapidly evolving industry.

Show more
Loading
CURA
S&P TSX Composite Index (Canada)
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 5, 2025
AI Summary
Q3 2025

Revenue: Curaleaf reported Q3 revenue of $320 million, up 2% quarter-over-quarter, despite ongoing price compression headwinds.

International Growth: The International segment delivered 12% sequential and 56% year-over-year revenue growth, led by strong performance in the U.K. and Germany.

Margins: Adjusted gross margin improved to 50%, up 115 basis points both sequentially and year-over-year, driven by cost reductions.

EBITDA: Adjusted EBITDA was $69 million with a 22% margin, but down 8% compared to last year, and impacted by international and hemp businesses.

Product Innovation: New product launches like the Anthem pre-roll and ACE extraction oil are driving higher customer engagement and strong sales.

Cash Flow & Liquidity: Generated $53 million in operating cash flow, closed a $100 million upsized credit line, and ended the quarter with $107 million in cash.

Guidance: Management expects Q4 revenue to increase low single digits sequentially from Q3.

Key Financials
Revenue
$320 million
International Segment Revenue Growth
56% year-over-year
International Segment Revenue Growth (QoQ)
12% sequential growth
Adjusted Gross Margin
50%
Adjusted EBITDA
$69 million
Adjusted EBITDA Margin
22%
Net Loss from Continuing Operations
$54.5 million
Adjusted Net Loss from Continuing Operations
$48.2 million
Operating Cash Flow from Continuing Operations
$53 million
Free Cash Flow from Continuing Operations
$37 million
Cash and Cash Equivalents
$107 million
Capital Expenditures
$16 million (Q3); $60 million (expected for 2025)
Outstanding Debt
$544 million
Retail Revenue
$226 million
Wholesale Revenue
$90 million
SG&A Expenses
$110 million
Core SG&A
$105 million
Inventory
$2 million increase year-over-year
Earnings Call Recording
Other Earnings Calls

Management

Mr. Boris Alexis Jordan
CEO & Chairman
No Bio Available
Mr. Joseph F. Lusardi
Executive Vice-Chairman
No Bio Available
Mr. Edward Kremer
Chief Financial Officer
No Bio Available
Mr. Matthew S. Darin
Special Advisor
No Bio Available
Mr. Camilo Russi Lyon
Chief Investment Officer
No Bio Available
Ms. Christine Taylor
Chief Accounting Officer
No Bio Available
Mr. Scott Baughman
Chief Technology Officer
No Bio Available
Mr. Jakob Feinstein
Manager of Investor Relations
No Bio Available
Mr. James S. Shorris
Chief Compliance Officer
No Bio Available
Ms. Kate Lynch
Executive Vice President of Marketing
No Bio Available

Contacts

Address
NEW YORK
New York City
420 Lexington Avenue
Contacts
+17814510117
ir.curaleaf.com